$1bn Deal Boosts Takeda, Arrowhead’s Liver Disease And RNAi Ambitions
Follows Promising Recent Clinical Data
Executive Summary
Takeda's global deal for one of US RNAi specialist's lead assets follows recent promising clinical results in serious disorder with no current therapeutic options.
You may also be interested in...
Asia Deal Watch: Rhizen Licenses Chinese Rights For PI3K Inhibitor To Curon
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Quick Listen: Scrip’s Five Must-Know Things
Join us for a brief audio roundup of the major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Vertex Suffers Setback In Its Search For Post-CF Blockbusters
Vertex has become a biotech investor favorite amid the tumult of 2020, but the potential of its pipeline is now under question.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports